If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 51 - 60 of 292
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Infusion of Danavorexton in Participants With Moderate to Severe Obstructive Sleep
Intravenous Danavorexton v Placebo in Moderate to Severe Sleep Apnea
Protocol No
ANES-TAKEDA-TAK-925-1501
Categories
A Multicenter Study to Assess the Safety and Effectiveness of the Genio Dual-sided Hypoglossal Nerve Stimulation System for the Treatment of Obstructive Sleep Apnea in Adults Subjects
Dual-sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea (DREAM)
Protocol No
OTO-NYXOAH-DREAM-STUDY
Categories
A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High-Risk Retroperitoneal Sarcoma (RPS) (EORTC-1809: STRASS 2)
A randomized study investigating preoperative chemotherapy followed by surgery versus surgery alone in patients with high risk retroperitoneal sarcoma (STRASS2)
Protocol No
ECOG-EA7211
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC
Testing Maintenance Immunotherapy Versus Observation in Patients With Oropharynx Cancer
Protocol No
ECOG-EA3161
Categories
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintena
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients with High Risk Rhabdomyosarcoma.
Protocol No
FH-COG-ARST2031
A Phase 1/2, Open-Label Study of PD-1 Knockout Tumor-Infiltrating Lymphocytes (IOV-4001) in Participants with Unresectable or Metastatic Melanoma or Stage III or IV Non-Small-Cell Lung Cancer
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Protocol No
IOVANCE-IOV-GM1-201
Categories
Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
The purpose of this part of this study is to compare the effects, good and/or bad, of the standard treatment (radiation therapy and cisplatin) with one of the experimental treatments chosen from the first part of the study (either radiation therapy and docetaxel or radiation therapy, cetuximab, and docetaxel) to find out which is better.
Protocol No
RTOG-1216
Categories
A Phase 1/2, Multicenter, Open-label, Single Arm, Dose Escalation and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive
A Phase 1/2, Study of Gilteritinib, Venetoclax and Azacitidine in Patients with AML
Protocol No
ASTELLAS-2215-CL-0203
Categories
A Randomized Phase II Study of INC280 (Capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
Comparing drugs for advanced non-small cell lung cancer with EGFR and MET gene changes
Protocol No
SWOG-S1900G
Categories
Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
Protocol No
ALLIANCE-A022001-PNETS
Categories